Thymosin Alpha-1 vs LL-37
Thymic Peptide · Cathelicidin Antimicrobial Peptide
Here is how these two compounds compare, based on published research, not marketing claims.
Thymosin Alpha-1
Enhances T-cell function and adaptive immune balance; internationally approved as Zadaxin for immune support in 35+ countries.
LL-37
Directly kills bacteria and fungi through membrane disruption while coordinating innate immune responses; the only human cathelicidin peptide.
Thymosin Alpha-1
856 studies
61 human trials
Not FDA-Approved
LL-37
3096 studies
7 human trials
Not FDA-Approved
What it does
Thymosin Alpha-1
Holds the broadest international clinical adoption of any thymic peptide. Approved as Zadaxin in over 35 countries for hepatitis B, hepatitis C, and immune support during chemotherapy. FDA orphan-drug designation in the United States. Works by activating dendritic cells (the immune system's sentinel cells) through Toll-like receptor 9, which then drives T-cell maturation. The published mechanism pushes the immune system toward attacking infected or abnormal cells directly, rather than primarily producing antibodies.
LL-37
Directly kills bacteria, fungi, and some viruses by disrupting their cell membranes, while simultaneously modulating the broader immune response to coordinate defense and wound healing. The only cathelicidin antimicrobial peptide produced by the human body.
How it works
Thymosin Alpha-1
Thymosin Alpha-1 binds Toll-like receptors (TLR2 and TLR9) on dendritic cells, the immune system's sentinel cells that present invaders to T-cells. That binding tilts the immune balance toward cell-mediated (Th1) responses over antibody-dominated (Th2) responses. It also activates natural killer cells and increases interferon production. The restorative profile, rather than broad stimulation, is what distinguishes it: benefit appears in immunocompromised populations (chronic hepatitis, cancer adjunct, elderly vaccine recipients) but is less clear in healthy adults with normal immune function.
LL-37
LL-37 is a 37-amino-acid peptide cleaved from its precursor protein hCAP-18. It functions through a dual mechanism: direct antimicrobial action and immunomodulation. The antimicrobial action works by inserting into and disrupting microbial cell membranes, physically destroying bacteria and fungi. The immunomodulatory function works by recruiting immune cells to infection sites, modulating inflammatory cytokine production, and supporting wound healing. LL-37 is produced by neutrophils, epithelial cells, and other immune cells as part of the innate immune defense. Its expression is partially regulated by vitamin D, which is why vitamin D deficiency is associated with increased susceptibility to certain infections.
How often
Thymosin Alpha-1
Subcutaneous injection in clinical trials and approved international use. Frequency and duration vary by indication in published trial protocols. Thymosin Alpha-1 is not FDA-approved in the United States; international use as Zadaxin follows country-specific prescribing guidelines.
LL-37
In published research, LL-37 has been studied in topical, injectable, and inhaled formulations across various infection and wound healing models. No FDA-approved LL-37 therapeutic product exists. The compound is available through research peptide markets. No standardized clinical dosing protocol has been established.
How strong
Thymosin Alpha-1
The most clinically validated peptide in PSI's library outside FDA-approved compounds. 856 published studies including 61 human trials. The strongest evidence is in chronic hepatitis B, where controlled trials show improved viral clearance when combined with interferon therapy. Cancer immunotherapy adjunct and vaccine adjuvant evidence is developing across multiple indications.
LL-37
Well-characterized as a fundamental component of human innate immunity. Published antimicrobial efficacy data across multiple pathogen types. The dual antimicrobial plus immunomodulatory mechanism is extensively documented. Human expression studies and vitamin D regulation pathway are well-established. Some clinical development programs (wound healing, infection) have been initiated but none have achieved FDA approval.
Main tradeoff
Thymosin Alpha-1
Approved in more than 35 countries since 1996; not approved in the United States. Both are true simultaneously, and the gap reflects an incomplete U.S. FDA approval process rather than a clinical failure. The EMA declined approval in 2006 on trial-design grounds. Whether the cancer immunotherapy adjunct evidence holds up in large checkpoint-inhibitor-era trials is empirically open. Whether healthy adults with normal immune function derive meaningful benefit is not established; most evidence is in immunocompromised populations.
LL-37
Extensively studied as an endogenous defense molecule but limited clinical development as a therapeutic. The antimicrobial mechanism (membrane disruption) is broad-spectrum but also raises concerns about host cell toxicity at higher concentrations. Stability and delivery challenges have limited clinical translation. The compound is well-understood biologically but not yet clinically validated as an exogenous therapeutic.
Best for
Thymosin Alpha-1
- Research interest in immune modulation through thymic peptide signaling
- Research focused on hepatitis B adjunct therapy where international approval evidence applies
- Research comparing immune-restorative versus immune-stimulatory compound profiles
LL-37
- Research on innate immune defense mechanisms and cathelicidin antimicrobial peptides
- Research on dual-function peptides that combine direct pathogen killing with immunomodulation
- Research comparing membrane-disrupting antimicrobials (LL-37) with NF-kB-suppressing anti-inflammatories (KPV)
How to choose
A good fit for Thymosin Alpha-1
- Research on adaptive immune modulation and T-cell function enhancement
- Research contexts where international clinical approval (Zadaxin) carries weight
- Research on immune support for chronic viral infections or immunodeficiency
A good fit for LL-37
- Research on innate antimicrobial defense mechanisms and membrane-disrupting peptides
- Research on the intersection of antimicrobial defense and wound healing
- Research on vitamin D-regulated immune peptides and their role in infection susceptibility
Consider both across time
Thymosin Alpha-1 and LL-37 address different arms of the immune system that work together in natural defense. Thymosin Alpha-1 orchestrates adaptive immunity (the targeted, learned immune response). LL-37 provides innate defense (the immediate, broad-spectrum response). For comprehensive immune research, both arms are relevant. Thymosin Alpha-1 has the clinical validation (Zadaxin); LL-37 has the deeper basic science characterization as a fundamental immune molecule.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- TLR2 Receptor
- TLR9 Receptor
- TLR2 Receptor expressed on Dendritic Cells; TLR9 Receptor expressed on Dendritic Cells
- Dendritic Cells connects to T-cell Maturation
- T-cell Maturation connects to Th1 Immune Response
- Dendritic Cells connects to Natural Killer Cells
- Natural Killer Cells connects to Interferon Production
- Microbial Membrane Disruption
- Immune Cell Recruitment
- Immune Cell Recruitment modulates Inflammatory Modulation
- Immune Cell Recruitment supports Wound Healing Support
- Microbial Membrane Disruption kills Direct Pathogen Killing
- Inflammatory Modulation connects to Immune Response Modulation; Wound Healing Support connects to Immune Response Modulation
Thymosin Alpha-1 binds TLR2 and TLR9 on dendritic cells to promote T-cell maturation and Th1 immune balance.
LL-37 inserts into and disrupts microbial cell membranes while recruiting immune cells to infection sites.
Research Evidence
Thymosin Alpha-1 has more clinical evidence: international approval as Zadaxin in 35+ countries with decades of clinical use for chronic hepatitis B and immune support. LL-37 is extensively characterized as an endogenous immune molecule (thousands of published studies on its biology) but has limited clinical development as an exogenous therapeutic. The evidence structures are complementary: Thymosin Alpha-1 has therapeutic validation; LL-37 has fundamental immunology depth.
- 1.
For immune system support with clinical evidence, thymosin alpha-1 has significantly more human data.
- 2.
For antimicrobial applications or biofilm-related conditions. LL-37 has specific mechanistic advantages.
- 3.
For vaccine response enhancement, thymosin alpha-1 has published clinical data for this use.
- 4.
For an evidence-first approach to immune optimization, thymosin alpha-1 is the better-supported option.
Key Limitations
- •No head-to-head comparison has been conducted.
- •These peptides target different immune subsystems, making direct comparison imperfect.
- •LL-37's therapeutic development faces significant stability and delivery challenges.
- •Thymosin alpha-1's lack of FDA approval limits awareness in Western medicine.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Thymosin Alpha-1
"Thymosin alpha-1 is the best peptide for immune support"
Supported by published data
"People use it to prevent getting sick during travel"
Plausible but unproven
"It helped during long COVID recovery"
Anecdotal only
LL-37
"LL-37 cured my chronic infection"
Insufficient evidence
"LL-37 is the body's natural antibiotic"
Supported by evidence
Safety Comparison
Thymosin Alpha-1 has well-characterized safety from international clinical use: generally well-tolerated with injection site reactions as the primary concern. LL-37 is an endogenous peptide the body produces naturally, but exogenous therapeutic use raises potential concerns about host cell toxicity at higher concentrations (the membrane-disrupting mechanism is not perfectly selective for microbial membranes). Neither is FDA-approved.
Thymosin Alpha-1
Approved as Zadaxin in over 30 countries. Extensive clinical safety data spanning decades. Generally well-tolerated with minimal side effects.
LL-37
Limited human safety data for therapeutic use. Endogenous peptide, your body produces it naturally. Theoretical safety is favorable but clinical data is sparse.
What the Research Suggests
Thymosin alpha-1 has far more clinical evidence and regulatory validation. LL-37 is a fascinating antimicrobial peptide with strong biological rationale but minimal clinical data. They serve different immune functions and are not interchangeable.